Ocular hypertension and the risk of blindness.
van Gestel Aukje, Webers Carroll A B, Beckers Henny J M, Peeters Andrea, Severens Johan L, Schouten Jan S A G
AI Summary
This study modeled ocular hypertension, finding the 15-year risk of unilateral blindness is under 10% for both treated and untreated patients, informing clinical management decisions.
Abstract
Purpose
To estimate the risk of blindness in patients with ocular hypertension (OHT) using an appropriate model and current empirical data.
Design
A Markov model with data from a systematic literature review.
Methods
A Markov model with 3 health states was built: OHT, primary open-angle glaucoma (POAG), and unilateral blindness. Literature was searched for reports on conversion from OHT to POAG and progression from POAG to blindness, to estimate a range of annual conversion and progression probabilities. The model had a cycle length of 1 year.
Results
The 15-year risk estimates ranged from 3.1% to 9.4% in untreated, and from 0.9% to 8.6% in treated patients with OHT. The ranges were the result of differences in patient populations, treatments, and outcome definitions in currently available empirical data.
Conclusions
The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is <10%.
MeSH Terms
Shields Classification
Key Concepts4
The 15-year risk of unilateral blindness in untreated patients with ocular hypertension (OHT) ranged from 3.1% to 9.4%.
The 15-year risk of unilateral blindness in treated patients with ocular hypertension (OHT) ranged from 0.9% to 8.6%.
The best estimates for the 15-year risk of unilateral blindness in patients with ocular hypertension (OHT) are less than 10%, based on currently available empirical data and an appropriate model.
A Markov model with three health states (ocular hypertension, primary open-angle glaucoma, and unilateral blindness) was used to estimate the risk of blindness in patients with ocular hypertension.
Related Articles5
Glaucoma risk factor assessment and prevention: lessons from coronary heart disease.
ReviewReferral for suspected glaucoma.
Observational StudyThe Carmarthenshire Glaucoma Referral Refinement Scheme, a safe and efficient screening service.
Observational StudyAge-period-cohort analysis of the global burden of visual impairment according to major causes: an analysis of the Global Burden of Disease Study 2019.
Cohort StudySocial determinants of health and health disparities in glaucoma: A review.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.